骨肉瘤患者血清miRNA-21水平与化疗敏感性和预后的相关性

Correlation of serum miRNA-21 level with chemosensitivity and prognosis of patients with osteosarcoma

目的研究骨肉瘤患者血清miRNA-21(miR-21)水平与化疗敏感性和预后的相关性。方法选取2016年8月至2017年8月于山西省肿瘤医院就诊的68例骨肉瘤患者,患者入院后均接受常规化疗,随访1年。根据患者化疗是否有效分为有效组(52例)和无效组(16例),记录两组患者的临床病理特征,应用单因素logistic回归模型分析骨肉瘤患者血清miR-21水平与化疗敏感性的关系,采用受试者工作特征(ROC)曲线评价血清miR-21预测预后的效能。结果有效组患者血清miR-21相对表达量高于无效组(6.6±0.7比5.2±0.7),有效组肿瘤转移率低于无效组[33.9%(18/52)比37.5%(6/16)],差异均有统计学意义(均P<0.05)。两组患者性别、年龄、体质量指数(BMI)、肿瘤位置、肿瘤大小以及TNM分期比较,差异均无统计学意义(均P>0.05)。logistic回归模型显示,血清miR-21和转移是影响化疗敏感性的因素(均P<0.05)。血清miR-21预测骨肉瘤患者预后的ROC曲线下面积(AUC)为0.774,Youden指数提示血清miR-21预测骨肉瘤患者预后的最佳截点为6.25。结论骨肉瘤患者血清miR-21水平与化疗敏感性及预后有关,能够作为预测患者化疗效果及预后的有效指标。

Objective To study the correlation between serum miRNA-21 (miR-21) level and chemosensitivity and prognosis of osteosarcoma patients. Methods A total of 68 osteosarcoma patients who were treated in Shanxi Provincial Cancer Hospital from August 2016 to August 2017 were selected. All patients received routine chemotherapy after admission. They were followed up for one year. According to the effectiveness of chemotherapy, they were divided into effective group (52 cases) and ineffective group (16 cases). The general clinicopathological characteristics of the two groups were recorded. Univariate logistic regression model was used to analyze the serum miR-21 level and chemosensitivity in osteosarcoma patients. The prognostic efficacy of serum miR-21 was evaluated by receiver operating characteristic (ROC) curve. Results The serum miR-21 expression in the effective group was higher than that in the ineffective group (6.6±0.7 vs. 5.2±0.7), and the tumor metastasis rate in the effective group was lower than that in the ineffective group [33.9%(18/52) vs. 37.5%(6/16)], and the differences between the two groups were statistically significant (both P < 0.05). There were no significant differences in gender, age, body mass index (BMI), tumor location, size of tumors and TNM stage between the two groups (all P > 0.05). Univariate logistic regression model showed that serum miR-21 and metastasis were the factors affecting chemosensitivity (both P < 0.05). ROC curve showed that the area under the curve (AUC) of using serum miR-21 to predict the prognosis of osteosarcoma patients was 0.774. Youden index indicated that the best cut-off points of serum miR-21 and chemosensitivity for predicting the prognosis of osteosarcoma patients was 6.25. Conclusion Serum miR-21 level in osteosarcoma patients is significantly correlated with chemosensitivity and prognosis, and it can be used as an effective index to predict the effect of chemotherapy and prognosis of patients with osteosarcoma.